BUT YOU HAVE KNOWN THIS FOR THE LAST YEAR!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! YOU CAN'T BE THIS DUMB!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! CAN YOU????????????????????????????? LOL
Lol, Root! I got side swiped as well, but not just by OXGN, by OVIT, MSTX and INNV as well! Oh and thanks to Hillary and Martin Shrikeli as well. As you and others have stated so many times, Schweity and the BOD is only concerned with keeping their inflated salaries around, it appears they will never sell, partner, or bring anything to market.
Did i mention 2 ceos since petey.Englands own taidaikai and billy(multiple shots on goal and increase shareholder value)schweiterman
2.rootbud breathed ate and dreamed oxgn 24 7
3.Best news in years
4.we had underwent 2 prior rses.not that long before
5.EA was our goto poster
So so much has changed for oxgn longs. Since then
ALL FOR THE WORSE.
3 offerings and another rs looking us in the face with another possible offering on the horizon.
OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, today announced positive results from a randomized Phase 2 clinical trial evaluating Avastin®(bevacizumab) with or without ZYBRESTAT® (fosbretabulin; CA4P) to treat patients with recurrent ovarian cancer. The study, known as Gynecologic Oncology Group protocol 186I, met its primary endpoint of a statistically significant increase in progression-free survival (p-value less than 0.05; hazard ratio 0.685) for the combination as compared to bevacizumab alone.
The Phase 2 study is being conducted by the GOG under the sponsorship of the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). It is the first and currently only randomized trial to test an antiangiogenic therapeutic agent combined with a vascular disrupting agent, without including any cytotoxic chemotherapy.
"These findings validate both the novel approach and the complementary mechanisms of combining the vascular disrupting agent fosbretabulin and an antiangiogenic agent like bevacizumab in patients with ovarian cancer," said Bradley J. Monk, M.D., FACS, FACOG, principal investigator for the trial, and professor and director, Division of Gynecologic Oncology and Department of Obstetrics and Gynecology at the University of Arizona Cancer Center. "This promising combination warrants further evaluation particularly given the significant need for new treatment options in relapsed ovarian cancer."
As previously reported, the GOG protocol 186I enrolled 107 patients with platinum-sensitive and -resistant recurrent ovarian cancer at 67 clinical sites in the U.S. Patients were randomized 1:1 into one of two treatment arms: one arm received Avastin, and the second arm received Avastin plus ZYBRESTAT. Both therapies were administered intravenously every three weeks and patients were treated until disease progression or until adverse effects prohibited further therapy.
Secondary endpoints in the study include safety, objective response rate (measured according to RECIST criteria) and overall survival. Patients receiving the combination of ZYBRESTAT and Avastin achieved a higher objective response rate, which was not statistically significant. All patients will continue to be followed for overall survival. Consistent with prior clinical experience with ZYBRESTAT, patients in the combination arm experienced a higher incidence of hypertension compared to the control arm. All cases of hypertension were managed with antihypertensive treatments, as specified in the study protocol. It is expected that the full study results will be submitted for presentation at a future scientific meeting.
For this study, ZYBRESTAT is provided to CTEP under aCooperative Research and Development Agreement (CRADA) with OXiGENE and bevacizumab is being provided as an investigational agent under a CRADA with Genentech. Bevacizumab is not approved to treat women with ovarian cancer in the U.S.; however, it is approved in other countries for treatment of ovarian cancer.
"We are very excited about these positive results and greatly appreciate all the patients who enrolled in this study and the support, resources and commitment of GOG and CTEP to conduct this important program," said Peter Langecker, M.D., Ph.D., chief executive officer of OXiGENE. "ZYBRESTAT is the first vascular disrupting agent to show a statistically significant progression-free survival benefit, and we are evaluating next steps to advance this combination to patients in need."
These guys have no sense of accountability. They should have been fired with a decent BOD.
Definately No from me. They keep insulting shareholders and treat us like idiots. Does the worst CEO even has right mind. Can't wait to vote everything down.
Completely agree. The BOD is a joke. How they selected such an incompetent CEO? He distroyes the company, let's eliminate his job. All BOD members should be held accountable. I support a legal action.
No on 2 denies the 1500000 added and will require the maximum amount to be issued to drop by the same split ratio. This is the most telling statement in the entire Def 14, they want us to take a 5 to 10 reverse split but they write in the proposal that management hand outs are not ratio to the split. So the split acts like a multyplier to their share options. This is for future options awards. Current is 500,000 after 10 to 1 split they are proposing 500,000 it should be 50,000.
It is in the details on Question 2. If we approve question 2 we add 1,500,000 shares to the management slush fund. The total count of incentive shares 5 to 6 million will get hit by the split. However. It says what I posted yesterday the maximum allotted amount to any one person in any one year is 500,000. They tried to give Scweity beyond 500,000 this year and amended it. So very clearly, they intend to give away the entire lot next spring. 5 to 6 million shares for no results
Let's take your money, let the stock slide outta compliance, cancel 2 quarterly calls in a row, cancel programs, delay others, collect paychecks, bonuses, options and then do a reverse split and keep the cycle of shareholder destruction going .... VOTE NO!!!! I'm flippin' mad!